Article (Scientific journals)
Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients.
Beguin, Yves
2002In Haematologica, 87 (11), p. 1209-21
Peer Reviewed verified by ORBi
 

Files


Full Text
Predict6.Amgen.Haematologica.pdf
Publisher postprint (206.25 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Algorithms; Anemia/drug therapy/etiology; Data Collection; Dose-Response Relationship, Drug; Erythropoietin, Recombinant/therapeutic use; Humans; Neoplasms/complications/drug therapy; Prognosis; Treatment Outcome
Abstract :
[en] BACKGROUND AND OBJECTIVES: The majority of cancer patients suffer from chronic anemia. While recombinant human erythropoietin (rHuEPO) offers many of the advantages of blood transfusions, response rates to this treatment are variable and in some trials a large proportion of patients (30 50%) did not respond. This failure may be due to factors related to the underlying disease, the chemotherapy given or functional iron deficiency. An accurate means of predicting response to rHuEPO would be beneficial to both healthcare providers and patients. EVIDENCE AND INFORMATION SOURCES: Data were identified by searches of the published literature, including PubMed, references from relevant reviews, and abstracts presented at recent international oncology and hematology meetings. Only papers in English published between 1990 and 2002 were included. References were selected according to direct relevance to the topic discussed and availability. STATE OF THE ART: The best algorithms for predicting response appear to be those combining an assessment of the adequacy of endogenous erythropoietin production together with some early indicators of erythropoietic marrow response. Further characterization of the dose-response relationship of erythropoietic agents may allow better understanding of ways in which response may be enhanced. Adequate iron availability could also contribute to better response rates. PERSPECTIVES: Further characterization of the predictors of response for current and upcoming erythropoietic agents may enhance the management of anemia associated with cancer, and provide more convenient, effective, and flexible therapy.
Disciplines :
Hematology
Author, co-author :
Beguin, Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients.
Publication date :
2002
Journal title :
Haematologica
ISSN :
0390-6078
eISSN :
1592-8721
Publisher :
Ferrata Storti Foundation, Pavia, Italy
Volume :
87
Issue :
11
Pages :
1209-21
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 16 February 2009

Statistics


Number of views
61 (0 by ULiège)
Number of downloads
120 (0 by ULiège)

Scopus citations®
 
54
Scopus citations®
without self-citations
43

Bibliography


Similar publications



Contact ORBi